[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR10149A - Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico - Google Patents

Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico

Info

Publication number
CR10149A
CR10149A CR10149A CR10149A CR10149A CR 10149 A CR10149 A CR 10149A CR 10149 A CR10149 A CR 10149A CR 10149 A CR10149 A CR 10149A CR 10149 A CR10149 A CR 10149A
Authority
CR
Costa Rica
Prior art keywords
therapeutic use
cytotoxic agents
understanding new
tomaimycin
tomaimycin derivatives
Prior art date
Application number
CR10149A
Other languages
English (en)
Inventor
Laurence Gauzy
Robert Zhao
Yonghong Deng
Wei Li
Hervé Bouchard
Ravi V J Chari
Alain Commercon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35953949&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10149(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CR10149A publication Critical patent/CR10149A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos derivados de tomaimicina, a su procedimiento de preparación y a sus usos terapéuticos.
CR10149A 2006-01-25 2008-07-16 Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico CR10149A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06290154A EP1813614B1 (en) 2006-01-25 2006-01-25 Cytotoxic agents comprising new tomaymycin derivatives

Publications (1)

Publication Number Publication Date
CR10149A true CR10149A (es) 2008-10-29

Family

ID=35953949

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10149A CR10149A (es) 2006-01-25 2008-07-16 Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico

Country Status (39)

Country Link
US (1) US8163736B2 (es)
EP (4) EP1813614B1 (es)
JP (1) JP5116696B2 (es)
KR (1) KR101428112B1 (es)
CN (1) CN101374846B (es)
AR (1) AR059201A1 (es)
AT (1) ATE527262T1 (es)
AU (1) AU2007209072C1 (es)
BR (1) BRPI0707264A2 (es)
CA (1) CA2635482C (es)
CR (1) CR10149A (es)
CY (2) CY1112495T1 (es)
DK (2) DK1813614T3 (es)
DO (1) DOP2007000016A (es)
EA (1) EA017196B1 (es)
EC (1) ECSP088632A (es)
ES (2) ES2374964T3 (es)
GT (1) GT200800147A (es)
HK (1) HK1129106A1 (es)
HN (1) HN2008001103A (es)
HR (2) HRP20110955T1 (es)
IL (1) IL192472A0 (es)
MA (1) MA30226B1 (es)
ME (1) ME01814B (es)
MX (1) MX2008009582A (es)
MY (1) MY157715A (es)
NI (1) NI200800207A (es)
NO (1) NO341074B1 (es)
NZ (1) NZ569789A (es)
PE (1) PE20071110A1 (es)
PL (2) PL1813614T3 (es)
PT (2) PT1813614E (es)
RS (2) RS52060B (es)
SI (2) SI1813614T1 (es)
TN (1) TNSN08283A1 (es)
TW (1) TWI389909B (es)
UA (1) UA97794C2 (es)
WO (1) WO2007085930A1 (es)
ZA (1) ZA200805649B (es)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000709A (es) 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
ES2435779T3 (es) * 2007-07-19 2013-12-23 Sanofi Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
GB0819097D0 (en) * 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
KR102021728B1 (ko) 2009-02-05 2019-09-16 이뮤노젠 아이엔씨 신규한 벤조디아제핀 유도체
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
BR112012020102A2 (pt) 2010-02-10 2016-11-29 Immunogen Inc anticorpos cd20 e usos dos mesmos.
AU2011239507B2 (en) * 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US8697688B2 (en) * 2010-04-15 2014-04-15 Seattle Genetics Inc. Pyrrolobenzodiazepines used to treat proliferative diseases
BR112012026801B8 (pt) 2010-04-15 2021-05-25 Medimmune Ltd conjugados de pirrolobenzodiazepina direcionados, composição farmacêutica, uso dos mesmos para tratamento de uma doença proliferativa ou autoimune e ligante de medicamento
FR2963007B1 (fr) * 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
MY183977A (en) 2011-02-15 2021-03-17 Immunogen Inc Cytotoxic benzodiazepine derivatives
WO2012145112A2 (en) 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
KR101860174B1 (ko) 2011-09-20 2018-05-21 메디뮨 리미티드 표적 접합체 내의 내포를 위한 비대칭 이량체 pbd 화합물로서 피롤로벤조디아제핀
JP6170497B2 (ja) 2011-10-14 2017-07-26 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピン
EP2755642B1 (en) 2011-10-14 2018-07-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013055987A1 (en) * 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
CA2850264C (en) 2011-10-14 2019-11-05 Spirogen Sarl Pyrrolobenzodiazepines
MX358757B (es) 2011-10-14 2018-09-03 Seattle Genetics Inc Pirrolobenzodiazepinas y conjugados dirigidos.
US9676850B2 (en) 2012-02-24 2017-06-13 Abbvie Stemcentrx Llc Anti SEZ6 antibodies and methods of use
SG10201806867VA (en) 2012-02-24 2018-09-27 Abbvie Stemcentrx Llc Dll3 modulators and methods of use
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
SG11201407106XA (en) 2012-05-01 2014-11-27 Genentech Inc Anti-pmel17 antibodies and immunoconjugates
CA2869777C (en) 2012-05-15 2021-11-16 Seattle Genetics, Inc. Self-stabilizing linker conjugates
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
BR112015000437A2 (pt) 2012-07-09 2017-06-27 Genentech Inc imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
JP2015527318A (ja) 2012-07-09 2015-09-17 ジェネンテック, インコーポレイテッド 抗cd22を含む免疫複合体
RU2015106673A (ru) 2012-08-02 2016-09-20 Дженентек, Инк. Антитела к рецептору эндотелина типа в (etbr) и иммуноконъюгаты
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
EP2906251B1 (en) 2012-10-12 2017-09-27 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
PT2766048E (pt) * 2012-10-12 2015-02-25 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
WO2014057119A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
AU2013328673B2 (en) 2012-10-12 2017-07-13 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
KR20200003278A (ko) 2012-10-12 2020-01-08 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
JP6392763B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーAdc Therapeutics Sa ピロロベンゾジアゼピン−抗体結合体
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
AU2012395148B2 (en) 2012-11-24 2016-10-27 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
AU2013366490B9 (en) 2012-12-21 2018-02-01 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
EP2935268B2 (en) 2012-12-21 2021-02-17 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP2745876A1 (en) 2012-12-21 2014-06-25 Prous Institute for Biomedical Research, S.A. Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives
CA2901114C (en) 2013-02-22 2020-01-07 Stemcentrx, Inc. Novel antibody conjugates and uses thereof
AR096287A1 (es) * 2013-03-13 2015-12-23 Spirogen Sàrl Pirrolobenzodiacepinas y conjugados
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
KR20150127199A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 항-b7-h4 항체 및 면역접합체
CN105636612B (zh) 2013-08-12 2020-01-14 基因泰克公司 抗体-药物缀合物及使用和治疗方法
PE20160674A1 (es) 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
BR112016004245A2 (pt) 2013-08-28 2017-10-17 Stemcentrx Inc moduladores de sez6 e métodos de uso
CA2921982C (en) * 2013-09-02 2020-08-25 Hangzhou Dac Biotech Co., Ltd Novel cytotoxic agents for conjugation of drugs to cell binding molecule
KR20160055252A (ko) 2013-09-17 2016-05-17 제넨테크, 인크. 항-lgr5 항체의 사용 방법
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
DK3057585T3 (da) 2013-10-15 2020-10-19 Seagen Inc Pegylerede lægemiddel-linkere til forbedret ligandlægemiddelkonjugat-farmakokinetik
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
EP3080607A4 (en) 2013-12-12 2017-07-12 AbbVie Stemcentrx LLC Novel anti-dpep3 antibodies and methods of use
JP6502942B2 (ja) 2013-12-13 2019-04-17 ジェネンテック, インコーポレイテッド 抗cd33抗体とイムノコンジュゲート
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CA3211226A1 (en) 2014-02-11 2015-08-20 Seagen Inc. Selective reduction of proteins
MX2016010677A (es) 2014-02-21 2017-04-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma.
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
GB201407816D0 (en) 2014-05-02 2014-06-18 King S College London Pyrrolobenzodiazepine Compounds
RU2016150370A (ru) 2014-05-22 2018-06-26 Дженентек, Инк. Антитела и иммуноконъюгаты против GPC3
WO2016008112A1 (en) 2014-07-16 2016-01-21 Medshine Discovery Inc. Linkers and application towards adc thereof
EP4074735A1 (en) 2014-08-28 2022-10-19 BioAtla, Inc. Conditionally active chimeric antigen receptors for modified t-cells
MA40539A (fr) * 2014-09-02 2016-03-10 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicaments
WO2016036804A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
WO2016036801A1 (en) 2014-09-03 2016-03-10 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗mfi2抗體及使用方法
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2015314826A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP7085837B2 (ja) 2014-09-12 2022-06-17 ジェネンテック, インコーポレイテッド 抗her2抗体及び免疫複合体
MX2017003022A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados.
US10059768B2 (en) 2014-09-12 2018-08-28 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CA2959689A1 (en) 2014-09-17 2016-03-24 Genentech, Inc. Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
EP3197500A1 (en) 2014-09-17 2017-08-02 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
PE20171184A1 (es) 2015-01-14 2017-08-22 Bristol Myers Squibb Co Dimeros de benzodiazepina, conjugados de estos, y sus metodos de preparacion y uso
CN107231804B (zh) 2015-01-14 2019-11-26 百时美施贵宝公司 亚杂芳基桥连苯并二氮杂*二聚体、其缀合物及制备和使用方法
US9504694B2 (en) 2015-03-19 2016-11-29 Cellerant Therapeutics, Inc. Isoquinolidinobenzodiazepines
MX2017012982A (es) 2015-04-10 2018-07-06 Univ Jefferson Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
BR112017027258A2 (pt) 2015-06-23 2018-08-28 Bristol-Myers Squibb Company dímeros de benzodiazepina macrocíclicos, conjugados dos mesmos, preparação e usos
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
PL3325482T3 (pl) 2015-07-21 2021-01-11 Immunogen, Inc. Sposoby otrzymywania cytotoksycznych pochodnych benzodiazepiny
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
MA43835A (fr) 2016-03-25 2018-11-28 Seattle Genetics Inc Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
KR20180126079A (ko) 2016-04-15 2018-11-26 바이오아트라, 엘엘씨 항 Axl항체, 항체 단편 및 이의 면역접합체와 이것들의 용도
AU2017254674A1 (en) 2016-04-21 2018-11-01 Abbvie Stemcentrx Llc Novel anti-BMPR1B antibodies and methods of use
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗muc1類美登素免疫綴合物抗體治療腫瘤的治療方案
IL308504A (en) 2016-05-13 2024-01-01 Bioatla Llc Antibodies, Antibody Fragments and Their Immunomodules Against ROR2 and Their Uses
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
EP3494135A1 (en) 2016-08-02 2019-06-12 The United States of America, as represented by The Secretary, Department of Health and Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
BR112019001945A2 (pt) 2016-08-09 2019-05-07 Seattle Genetics, Inc. composição de conjugado de fármaco aglutinante, formulação farmaceuticamente aceitável, métodos para tratar uma doença ou afecção hiperproliferativa, para inibir a multiplicação de uma célula tumoral ou célula cancerígena e para preparar uma composição de conjugado de fármaco aglutinado, e, composto
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用
US11697680B2 (en) 2016-11-21 2023-07-11 Cureab Gmbh Anti-GP73 antibodies and immunoconjugates
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CA3045902A1 (en) 2016-12-21 2018-06-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for flt3 and uses thereof
PL3544636T3 (pl) 2017-02-08 2021-12-06 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
PT3579883T (pt) 2017-02-08 2021-09-28 Medimmune Ltd Conjugados de pirrolobenzodiazepina-anticorpo
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
EP3612537B1 (en) 2017-04-18 2022-07-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
PL3612234T3 (pl) 2017-04-20 2024-09-02 Adc Therapeutics Sa Terapia skojarzona z koniugatem anty-AXL przeciwciało-lek
US20180346488A1 (en) 2017-04-20 2018-12-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
AU2018268970B2 (en) 2017-05-19 2024-12-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
CA3064804A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
CA3066953A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
KR102312910B1 (ko) 2017-08-18 2021-10-15 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
US20200216463A1 (en) 2017-09-20 2020-07-09 Ph Pharma Co., Ltd. Thailanstatin analogs
CN117003875A (zh) 2017-09-29 2023-11-07 第一三共株式会社 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用
EP3705471A4 (en) * 2017-11-02 2021-08-11 UBE Industries, Ltd. DOUBLE-HEADED PROTEASE INHIBITOR
EP3710066B1 (en) 2017-11-14 2022-06-08 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) * 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
WO2019224340A1 (en) 2018-05-25 2019-11-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
AU2019301675A1 (en) 2018-07-12 2021-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof
US20210308275A1 (en) 2018-07-31 2021-10-07 Astrazeneca Ab Linkers and conjugates
AU2019317565A1 (en) 2018-08-08 2021-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
CA3112977A1 (en) 2018-10-19 2020-04-23 Medimmune Limited Pyrrolobenzodiazepine conjugates
US20210380605A1 (en) 2018-10-19 2021-12-09 Medimmune Limited Pyrrolobenzodiazepine conjugates
GB201820725D0 (en) 2018-12-19 2019-01-30 Adc Therapeutics Sarl Pyrrolobenzodiazepine resistance
EP3899048A1 (en) 2018-12-19 2021-10-27 ADC Therapeutics SA Pyrrolobenzodiazepine resistance
JP2022513482A (ja) 2018-12-21 2022-02-08 アビディティー バイオサイエンシーズ,インク. 抗トランスフェリン受容体抗体およびその使用
WO2020141923A2 (ko) * 2019-01-03 2020-07-09 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
WO2020146182A1 (en) 2019-01-08 2020-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
CA3125033A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
ES2967878T3 (es) 2019-03-15 2024-05-06 Medimmune Ltd Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
CA3133757A1 (en) 2019-03-29 2020-10-08 Medimmune Limited Compounds and conjugates thereof
US20230094471A1 (en) 2019-03-29 2023-03-30 Immunogen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
GB201908128D0 (en) 2019-06-07 2019-07-24 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN110483504B (zh) * 2019-08-02 2022-04-26 桂林理工大学 以DMF为甲酰化试剂构建2-(2-萘基)咪唑[1,2-a]吡啶-3-醛的新方法
US20240124938A1 (en) * 2019-10-16 2024-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Visual detection of pbd induced dna crosslinks
AU2020370125A1 (en) 2019-10-22 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting B7H3 (CD276) for treating multiple solid tumors
WO2021080608A1 (en) 2019-10-25 2021-04-29 Medimmune, Llc Branched moiety for use in conjugates
JP2023506158A (ja) 2019-12-12 2023-02-15 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ Cd276に特異的な抗体-薬物コンジュゲートおよびその使用
TW202140076A (zh) 2020-01-22 2021-11-01 英商梅迪繆思有限公司 化合物及其軛合物
AU2021210570A1 (en) 2020-01-22 2022-09-01 Medimmune Limited Compounds and conjugates thereof
JP2023537798A (ja) 2020-03-19 2023-09-06 アビディティー バイオサイエンシーズ,インク. 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法
TW202202173A (zh) 2020-03-27 2022-01-16 美商亞維代堤生物科學公司 治療肌肉萎縮症之組合物及方法
BR112022020332A2 (pt) 2020-04-10 2022-12-13 Seagen Inc Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
WO2022093745A1 (en) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CA3213625A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CA3213636A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
GB202105187D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB202105186D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
US20240270851A1 (en) 2021-06-09 2024-08-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
WO2023288252A1 (en) 2021-07-13 2023-01-19 Truebinding, Inc. Methods of preventing protein aggregation
GB202110726D0 (en) 2021-07-26 2021-09-08 Cambridge Entpr Ltd Conjugating reagents and conjugates thereof
CA3231330A1 (en) 2021-09-16 2023-03-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
TW202406934A (zh) 2022-05-03 2024-02-16 美商建南德克公司 抗Ly6E抗體、免疫結合物及其用途
GB202207691D0 (en) 2022-05-25 2022-07-06 Cambridge Entpr Ltd Quinone protected forms and conjugates
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4764368A (en) 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
AU7579991A (en) 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
EP1109812B1 (en) 1998-08-27 2005-05-04 Spirogen Limited Pyrrolobenzodiazepines
US6472056B1 (en) 1999-07-06 2002-10-29 Northwest Coatings Corp. Radiation-cured laminate label
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
MXPA02012438A (es) * 2000-06-16 2004-09-06 Dept Of Radiation Oncology Uni Columnas extracorporeas para uso repetido, cargadas con conjugados de ligando-dibiotina.
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
EP1608663B1 (en) * 2003-03-31 2008-11-05 Council of Scientific and Industrial Research Pyrrolo (2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
AU2004240541B2 (en) 2003-05-20 2009-08-20 Immunogen, Inc. Improved cytotoxic agents comprising new maytansinoids
GB0416511D0 (en) * 2003-10-22 2004-08-25 Spirogen Ltd Pyrrolobenzodiazepines
AU2004284075A1 (en) 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404578D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
WO2005085260A1 (en) 2004-03-09 2005-09-15 Spirogen Limited Pyrrolobenzodiazepines
GB0410725D0 (en) * 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents

Also Published As

Publication number Publication date
EP1813614A1 (en) 2007-08-01
PT1813614E (pt) 2012-01-09
IL192472A0 (en) 2009-02-11
ZA200805649B (en) 2009-11-25
NI200800207A (es) 2010-07-15
AU2007209072B2 (en) 2012-09-27
WO2007085930A1 (en) 2007-08-02
AU2007209072C1 (en) 2013-03-14
CY1115199T1 (el) 2017-01-04
ATE527262T1 (de) 2011-10-15
EP1981889A1 (en) 2008-10-22
TNSN08283A1 (en) 2009-10-30
ES2374964T3 (es) 2012-02-23
AU2007209072A1 (en) 2007-08-02
RS52060B (en) 2012-04-30
TWI389909B (zh) 2013-03-21
CY1112495T1 (el) 2015-12-09
SI1813614T1 (sl) 2012-01-31
PL1981889T3 (pl) 2014-06-30
EP1981889B1 (en) 2014-01-15
CA2635482A1 (en) 2007-08-02
PL1813614T3 (pl) 2012-03-30
DOP2007000016A (es) 2007-09-15
JP5116696B2 (ja) 2013-01-09
HRP20140307T1 (hr) 2014-06-20
GT200800147A (es) 2012-03-12
KR101428112B1 (ko) 2014-08-07
AR059201A1 (es) 2008-03-19
CA2635482C (en) 2012-05-22
SI1981889T1 (sl) 2014-05-30
ECSP088632A (es) 2008-08-29
EP2386559A1 (en) 2011-11-16
PE20071110A1 (es) 2007-12-21
BRPI0707264A2 (pt) 2011-04-26
MY157715A (en) 2016-07-15
NO20083427L (no) 2008-10-14
RS53293B (en) 2014-08-29
EP1813614B1 (en) 2011-10-05
EP2371827A1 (en) 2011-10-05
JP2009524636A (ja) 2009-07-02
KR20080097435A (ko) 2008-11-05
EA017196B1 (ru) 2012-10-30
HN2008001103A (es) 2011-12-01
PT1981889E (pt) 2014-04-29
US8163736B2 (en) 2012-04-24
CN101374846A (zh) 2009-02-25
ME01814B (me) 2014-09-20
NZ569789A (en) 2011-11-25
NO341074B1 (no) 2017-08-21
ES2457525T3 (es) 2014-04-28
HRP20110955T1 (hr) 2012-01-31
MX2008009582A (es) 2008-11-26
MA30226B1 (fr) 2009-02-02
DK1981889T3 (da) 2014-04-14
EA200870193A1 (ru) 2009-02-27
TW200806668A (en) 2008-02-01
HK1129106A1 (en) 2009-11-20
CN101374846B (zh) 2013-10-30
UA97794C2 (ru) 2012-03-26
DK1813614T3 (da) 2012-01-23
US20090036431A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
CR10149A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
CR20150401A (es) Formas de rifaximina y sus usos
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CO6741203A2 (es) Derivados de biciclo[3,2,1]octilamida y sus usos
HN2006037713A (es) Compuestos utiles en terapia
CR20110100A (es) Nuevos derivados de sulfamida sustituida
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
PA8781701A1 (es) Derivados de 7-alquinil-1,8- naftiridonas, su preparaciones y su aplicacion en terapeutica
HN2008001521A (es) Dimeros de derivados de artemisinina, su preparacion y su aplicacion en terapeutica
BRPI0620985B1 (pt) composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina
CO6290689A2 (es) Derivados de 1,2,3,4-tetrahidropirrolo[1,2]pirazina-6-carboxamidas y de 2,3,4,5-tetrahidropirrol[1,2][1,4]-diazepina -7-carboxamidas su preparacion y su aplicacion en terapeutica
PA8657801A1 (es) Aminalcoholes triciclicos, procedimientos para su preparacion
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
DOP2006000257A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
ECSP099679A (es) Nuevos compuestos y sus usos 707
UY31427A1 (es) Derivados 1,2,4-triazol amino como moduladores de mglur5
ECSP109874A (es) Nuevos compuestos 892
UY30235A1 (es) Inhibidores de la adenilato ciclasa soluble
NI201200103A (es) NUEVOS DERIVADOS ( HETEROCICLO - TETRAHIDRO - PIRIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y ( HETEROCICLO - DIHIDRO - PIRROLIDIN ) - ( PIPERAZINIL ) - 1 - ALCANONA Y SU UTILIZACIÓN COMO INHIBIDORES DE p75
ECSP088899A (es) Derivados de 2-alcoxi-3,4,5-trihidroxi-alquilamida, su preparación, composiciones que las contienen y utilización
DOP2007000059A (es) Inhibidores de la adenilato ciclasa soluble
DOP2007000060A (es) Inhibidores de la adenilato ciclasa soluble

Legal Events

Date Code Title Description
FC Refusal